5-Amino 1MQ
/ Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor (not a peptide; commonly sold in peptide-market channels)ALIAS · 5-Amino-1-methylquinolinium · NNMT inhibitor
Terms in this page you can click for a plain-English popup: , , , , , , , .
Preclinical development as an NNMT inhibitor for obesity and metabolic indications. No human trials published. Commonly sold in peptide-market channels despite not being a peptide.
5-Amino 1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and is elevated in obese adipose tissue. Proposed to restore NAD-related cellular metabolism and reduce adipocyte lipogenesis in preclinical obesity models.
Preclinical rodent models report reductions in adipose tissue and improvements in metabolic markers. No human trials have been published.
No human safety data. Long-term effects of sustained NNMT inhibition in humans are not characterized.
Regulatory status
- FDA status:
- Not FDA-approved
5-Amino 1MQ is a small molecule, not a peptide — inclusion in peptide-market catalogs is primarily a distribution-channel phenomenon, not a scientific category. All in-vivo efficacy data is preclinical.